1. Upton A, Marr KA. Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient. Current infectious disease reports. 2006 ;8(6):434-41.
2. Mulu A, Kassu A, Anagaw B, Moges B, Gelaw A, AlemayehuM et al. Frequent detection of ‘azole’ resistant Candida species among late presenting AIDS patients in north west Ethiopia BMC Infectious Diseases 2013, 13:82.
3. Yapar N. Epidemiology and risk factors for invasive candidiasis. Therapeutics and clinical risk management. 2014; 10:95.
4. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S. Antimicrobial-resistant pathogens associated with healthcare-associated infections summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infection Control & Hospital Epidemiology. 2013;34(1):1
5. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clinical infectious diseases. 2005;41(9):1232-9.
6. Zaragoza O, Mesa-Arango AC, Gómez-López A, Bernal-Martínez L, Rodríguez-Tudela JL, Cuenca-Estrella M. A process analysis of variables for standardization of antifungal susceptibility testing of non-fermentative yeasts. Antimicrobial agents and chemotherapy. 2011.
7. Melhem MS, Bertoletti A, Lucca HR, Silva RB, Meneghin FA, Szeszs MW. Use of the VITEK 2 system to identify and test the antifungal susceptibility of clinically relevant yeast species. Brazilian Journal of Microbiology. 2013;44(4):1257-66.
8. Donay JL, Mathieu D, Fernandes P, Pregermain C, Bruel P, Wargnier A, Casin I, Weill FX, Lagrange PH, Herrmann JL. Evaluation of the automated Phoenix system for potential routine use in the clinical microbiology laboratory. Journal of clinical microbiology. 2004;42(4):1542-.
9. Bitew A, Abebaw Y. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. BMC women's health. 2018;18(1):94.
10. Gunsilius E, Lass-Flörl C, Kähler CM, Gastl G, Petzer AL. Candida ciferrii, a new fluconazole-resistant yeast causing systemic mycosis in immunocompromised patients. Annals of hematology. 2001;80(3):178-9.
11. Liu W, Tan J, Sun J, Xu Z, Li M, Yang Q,etal.Inasive candidiasis in intensive care units in China: in vitro antifungal susceptibility in the China-SCAN study J Antimicrob Chemother. 2014; 69:162-
12. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, etal .Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Disease Society of America. Clin Infect Dis. 2016;62:409-17
13. Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. Journal of clinical microbiology. 2007; 1;45(11):3522-8.
14. Sanguinetti M, Porta R, Sali M, La Sorda M, Pecorini G, Fadda G, Posteraro B. Evaluation of VITEK 2 and RapID yeast plus systems for yeast species identification: experience at a large clinical microbiology laboratory. Journal of clinical microbiology. 2007;45(4):1343-6.
15. Okonkwo E C, Alo MN, Nworie O, Orji JO, Agah MV.Prevalence of oral candida albicans infection in HIVsero-positive patients in Abakaliki.American. Journal of Life Sciences. 2013; 1: 72-76.
16. Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. BioMed research international. 2013;2013
17. Banerjee P, Haider M, Trehan V, Mishra B, Thakur A, Dogra V, Loomba P. Cryptococcus laurentii fungemia. Indian journal of medical microbiology. 2013;31(1):75.
18. Vincent BM, Lancaster AK, Scherz-Shouval R, Whitesell L, Lindquist S. Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS biology. 2013;11(10):e1001692.
19. Adjapong G, Bartlett M, Hale M, Garrill A. The isolation of Candida rugosa and Candida mesorugosa from clinical samples in Ghana. Sabouraudia. 2015;54(3):322-6.
20. Colombo AL, Melo AS, Rosas RF, Salomão R, Briones M, Hollis RJ, Messer SA, Pfaller MA. Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagnostic microbiology and infectious disease. 2003;46(4):253-7
21. Minces LR, Ho KS, Veldkamp PJ, Clancy CJ. Candida rugosa: a distinctive emerging cause of candidaemia. A case report and review of the literature. Scandinavian journal of infectious diseases. 2009; 41(11-12):892-7.
22. You X, Li J, Li S, Shi W. Effects of lamellar keratectomy and intrastromal injection of 0.2% fluconazole on fungal keratitis. Journal of ophthalmology. 2015;2015
23. Moges B, Bitew A, Shewaamare A. Spectrum and the in vitro antifungal susceptibility pattern of yeast isolates in Ethiopian HIV patients with oropharyngeal candidiasis. International journal of microbiology. 2016; 2016.
24. Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Non-neoformans cryptococcal infections: a systematic review. Infection. 2007;35(2):51.
25. Bernal-Martinez L, Gomez-Lopez A, Castelli MV, Mesa-Arango AC, Zaragoza O, Rodriguez-Tudela JL, Cuenca-Estrella M. Susceptibility profile of clinical isolates of non-Cryptococcus neoformans/non-Cryptococcus gattii Cryptococcus species and literature review. Medical mycology. 2010;48(1):90-6
26. Smith N, Sehring M, Chambers J, Patel P. Perspectives on non-neoformans cryptococcal opportunistic infections. Journal of community hospital internal medicine perspectives. 2017;7(4):214-7.
27. Malini A, Oudeacoumar P, Udayashankar C. Onychomycosis due to Trichosporon mucoides. Indian Journal of Dermatology, Venereology, and Leprology. 2011;77(1):76.
28. Rizzitelli G, Guanziroli E, Moschin A, Sangalli R, Veraldi S. Onychomycosis caused by Trichosporon mucoides. International Journal of Infectious Diseases. 2016 ;42:61-3.